Recap: Werewolf Therapeutics Q4 Earnings
Portfolio Pulse from Benzinga Insights
Werewolf Therapeutics (NASDAQ:HOWL) reported Q4 earnings, beating estimated EPS by 23.0% with an EPS of $-0.33 versus an estimate of $-0.43. However, revenue was down $5.78 million from the same period last year. The company had previously beaten EPS estimates in Q3 2023, which was followed by a 0.0% change in share price the next day.
March 07, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Werewolf Therapeutics reported a better-than-expected Q4 EPS but saw a decrease in revenue compared to last year. The company has a history of beating EPS estimates.
The positive EPS beat could be seen as a sign of operational efficiency and could potentially offset concerns about the revenue decline in the short term. Given the company's history of beating EPS estimates, investor sentiment may remain cautiously optimistic. However, the significant revenue drop and the previous quarter's 0.0% share price movement post-earnings suggest a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100